诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NVO 诺和诺德

休市中 04-19 16:00:00 EDT

122.71

-0.04

-0.03%

盘后122.59

-0.12-0.10%

19:59 EDT

最高124.54	最低122.46	成交量518.35万
今开123.48	昨收122.75	日振幅1.69%
总市值5,475亿	流通市值3,921亿	总股本44.62亿
成交额6.39亿	换手率0.16%	流通股本31.95亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"NVO","market":"US","secType":"STK","nameCN":"诺和诺德","latestPrice":122.71,"timestamp":1713556800000,"preClose":122.75,"halted":0,"volume":5183469,"hourTrading":{"tag":"盘后","latestPrice":122.59,"preClose":122.71,"latestTime":"19:59 EDT","volume":220896,"amount":27098629.3594,"timestamp":1713571196894},"delay":0,"floatShares":3195271709,"shares":4461532793,"eps":2.761292,"marketStatus":"休市中","marketStatusCode":7,"change":-0.04,"latestTime":"04-19 16:00:00 EDT","open":123.48,"high":124.54,"low":122.46,"amount":639384768.017874,"amplitude":0.016945,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.761292,"exchange":"NYSE","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1713772800000},"adr":1,"listingDate":363499200000,"adjPreClose":122.75,"adrRate":1,"dividendRate":0.011274,"preHourTrading":{"tag":"盘前","latestPrice":123.5,"preClose":122.75,"latestTime":"09:29 EDT","volume":38240,"amount":4712839.8527999995,"timestamp":1713533397471},"postHourTrading":{"tag":"盘后","latestPrice":122.59,"preClose":122.71,"latestTime":"19:59 EDT","volume":220896,"amount":27098629.3594,"timestamp":1713571196894},"volumeRatio":1.705091},"requestUrl":"/m/hq/s/NVO","defaultTab":"news","newsList":[{"id":"2428506745","title":"2024财报｜突破400亿收入后，华东医药如何直面“降速”挑战","url":"https://stock-news.laohu8.com/highlight/detail?id=2428506745","media":"华尔街见闻","top":-1,"share":"https://www.laohu8.com/m/news/2428506745?lang=zh_cn&edition=full","pubTime":"2024-04-19 11:33","pubTimestamp":1713497608,"startTime":"0","endTime":"0","summary":"大手笔分红","market":"hk","thumbnail":"https://wpimg-wscn.awtmt.com/6ee4604f-d045-4793-963f-45e92ff1c379.png","type":0,"news_type":0,"thumbnails":["https://wpimg-wscn.awtmt.com/6ee4604f-d045-4793-963f-45e92ff1c379.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3713114","is_publish_highlight":false,"gpt_icon":0},{"id":"2428974865","title":"坎托菲茨杰拉德公司：重申Novo Nordisk(NVO.US)评级，由增持调整至增持评级, 目标价160.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2428974865","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2428974865?lang=zh_cn&edition=full","pubTime":"2024-04-18 22:05","pubTimestamp":1713449158,"startTime":"0","endTime":"0","summary":"坎托菲茨杰拉德公司：重申Novo Nordisk(NVO.US)评级，由增持调整至增持评级, 目标价160.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404182206018b36513b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404182206018b36513b&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427642927","title":"隔夜美股全复盘(4.13)| 三大股指集体收跌，中东紧张局势加剧，叠加部分美国大型银行股财报喜忧参半，美股连续第二周收跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2427642927","media":"格隆汇","top":-1,"share":"https://www.laohu8.com/m/news/2427642927?lang=zh_cn&edition=full","pubTime":"2024-04-13 07:16","pubTimestamp":1712963782,"startTime":"0","endTime":"0","summary":"三大股指集体收跌，中东紧张局势加剧，叠加部分美国大型银行股财报喜忧参半，美股连续第二周收跌","market":"us","thumbnail":"https://img7.gelonghui.com/column/2/140.png","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/140.png"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/718741","is_publish_highlight":false,"gpt_icon":0},{"id":"2426178655","title":"减肥药大利好! EMA官宣司美格鲁肽等药物与自杀念头无关联","url":"https://stock-news.laohu8.com/highlight/detail?id=2426178655","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2426178655?lang=zh_cn&edition=full","pubTime":"2024-04-12 20:03","pubTimestamp":1712923400,"startTime":"0","endTime":"0","summary":"EMA表示，根据该机构的调查和接受药物治疗的超重和2型糖尿病患者的电子健康记录，最终的结果不支持使用“GLP-1受体激动剂与这种风险之间的因果关系”。早在2023年7月，EMA对与司美格鲁肽和利拉鲁肽有关的导致自杀念头和自残报告展开了调查，这两种药物分别是诺和诺德旗下的畅销“减肥神药”Wegovy/Ozempic和Saxenda的主要活性成分。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1101985.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2426720676","title":"Novo Nordisk(NVO.US)获加拿大蒙特利尔银行首次覆盖，给予优于大市评级, 目标价163.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2426720676","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2426720676?lang=zh_cn&edition=full","pubTime":"2024-04-12 17:25","pubTimestamp":1712913900,"startTime":"0","endTime":"0","summary":"Novo Nordisk获加拿大蒙特利尔银行首次覆盖，给予优于大市评级, 目标价163.00美元。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/us/2024-04-12/doc-inarqier8968095.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/us/2024-04-12/doc-inarqier8968095.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2426409014","title":"投资5.56亿！诺和诺德扩展中国市场，肥胖新药潜力超230亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2426409014","media":"和讯网","top":-1,"share":"https://www.laohu8.com/m/news/2426409014?lang=zh_cn&edition=full","pubTime":"2024-04-11 11:54","pubTimestamp":1712807699,"startTime":"0","endTime":"0","summary":"诺和诺德加大对中国市场投入当地时间4月9日，诺和诺德宣布将投资约5.56亿美元用于升级和扩建其在中国天津的生产基地。该投资旨在提升公司在中国的生产能力，满足市场对创新药物的需求，并采用创新技术提升生产效率和产品质量。中国减肥药市场潜力巨大机构预测，未来6年中国的糖尿病及减肥药物市场规模将超过230亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041111550287654054&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041111550287654054&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426472515","title":"诺和诺德口服GLP-1和胰淀素受体双重激动剂Amycretin片临床试验申请获中国国家药监局受理，开辟减重治疗新篇章，相关产业链受关注","url":"https://stock-news.laohu8.com/highlight/detail?id=2426472515","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2426472515?lang=zh_cn&edition=full","pubTime":"2024-04-11 09:46","pubTimestamp":1712799985,"startTime":"0","endTime":"0","summary":"4月10日，中国国家药品监督管理局药品审评中心在其官方网站上公示，丹麦医药巨头诺和诺德提交的1类新药Amycretin片临床试验申请已被正式受理。Amycretin是一种新型口服GLP-1受体和胰淀素受体长效共激动剂，被视为新一代的减重疗法。诺和诺德最近公开的一项小型1期临床研究表明，在接受12周该药物治疗后，患者的体重平均下降了13.1%，相较于安慰剂组的1.1%降幅显著。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404110947388764a2da&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404110947388764a2da&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426420500","title":"港股概念追踪 | 诺和诺德减肥新药在华临床获批 产业将迎来成果突破爆发期(附概念股)","url":"https://stock-news.laohu8.com/highlight/detail?id=2426420500","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2426420500?lang=zh_cn&edition=full","pubTime":"2024-04-11 07:52","pubTimestamp":1712793165,"startTime":"0","endTime":"0","summary":"诺和诺德旗下的王牌减重药品是司美格鲁肽，注射剂型或将于今年年内在中国获批用于减重。诺和诺德2023年财报显示，减肥版司美格鲁肽Wegovy销售额暴涨406%达到46亿美元，在全球GLP-1赛道遥遥领先。目前，GLP-1药物在糖尿病和减肥药布局上，礼来、诺和诺德占据全球领先位置。诺和诺德的司美格鲁肽是全球首个销售额超百亿美元的GLP-1药物大单品。随着诺和诺德、礼来的GLP-1靶点减重药研发趋势，减重药产业迎来成果突破爆发期。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1100893.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2426422642","title":"隔夜美股全复盘(4.11)| 三大股指集体收跌，美国CPI数据连续第三个月高于预期，股市承压于美国CPI数据后的降息预期收缩，英伟达逆势涨近2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2426422642","media":"格隆汇","top":-1,"share":"https://www.laohu8.com/m/news/2426422642?lang=zh_cn&edition=full","pubTime":"2024-04-11 07:18","pubTimestamp":1712791107,"startTime":"0","endTime":"0","summary":"三大股指集体收跌，美国CPI数据连续第三个月高于预期，股市承压于美国CPI数据后的降息预期收缩，英伟达逆势涨近2%","market":"us","thumbnail":"https://img7.gelonghui.com/column/2/140.png","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/140.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/717886","is_publish_highlight":false,"gpt_icon":1},{"id":"2426415491","title":"BUZZ-古根海姆上调礼来和诺和诺德的目标价，继续看好减肥和糖尿病药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2426415491","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2426415491?lang=zh_cn&edition=full","pubTime":"2024-04-10 22:58","pubTimestamp":1712761118,"startTime":"0","endTime":"0","summary":"    4月10日 - ** 古根海姆在第一季度财报发布前上调了礼来  和诺和诺德  的预测值** 券商将礼来糖尿病药物Mounjaro和肥胖症药物Zepbound的2031年销售额预期从675.6亿美元上调至712.1亿美元** 将预测值从 780 美元上调至 855 美元，并称 \"最后，最重要的是 Mounjaro 和 Zepbound 的销售和供应\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2426349688","title":"诺和诺德新减肥药在华临床试验申请获受理，效果或优于司美格鲁肽","url":"https://stock-news.laohu8.com/highlight/detail?id=2426349688","media":"澎湃新闻","top":-1,"share":"https://www.laohu8.com/m/news/2426349688?lang=zh_cn&edition=full","pubTime":"2024-04-10 20:51","pubTimestamp":1712753460,"startTime":"0","endTime":"0","summary":"4月10日，中国国家药监局药品审评中心官网公示，诺和诺德1类新药Amycretin片的临床试验申请获得受理，药品类型为治疗用生物制品。以此推测，诺和诺德在中国递交临床试验申请的是也极有可能是Amycretin的口服版本，不过这一信息并未有官方证实。诺和诺德2023年财报显示，减肥版司美格鲁肽Wegovy销售额暴涨406%达到46亿美元，在全球GLP-1赛道遥遥领先。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404102052288b0a3b9c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404102052288b0a3b9c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"1176571603","title":"12周减重超13%，诺和诺德这款口服疗法在中国申报临床","url":"https://stock-news.laohu8.com/highlight/detail?id=1176571603","media":"老虎资讯综合","top":-1,"share":"https://www.laohu8.com/m/news/1176571603?lang=zh_cn&edition=full","pubTime":"2024-04-10 18:26","pubTimestamp":1712744814,"startTime":"0","endTime":"0","summary":"展现出快速减重的效果以及较好的临床应用潜力。","market":"us","thumbnail":"https://static.tigerbbs.com/18f2b626f44c944e5c600fc5a3dd71db","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/18f2b626f44c944e5c600fc5a3dd71db"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"gpt_icon":0},{"id":"2426746840","title":"12周减重超13%，诺和诺德1类新药amycretin片在中国申报临床-36氪","url":"https://stock-news.laohu8.com/highlight/detail?id=2426746840","media":"第一财经","top":-1,"share":"https://www.laohu8.com/m/news/2426746840?lang=zh_cn&edition=full","pubTime":"2024-04-10 18:04","pubTimestamp":1712743476,"startTime":"0","endTime":"0","summary":"中国国家药监局药品审评中心官网公示，诺和诺德1类新药amycretin片的临床试验申请获得受理。公开资料显示，这是诺和诺德开发的一款口服GLP-1受体和胰淀素受体的长效共激动剂，为新一代减重疗法。今年3月，诺和诺德公布了口服amycretin的最新临床试验结果。这是一项包含16位患者的小型1期试验，患者在接受治疗12周后其体重下降幅度达13.1%。（第一财经）","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404101804388b097949&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404101804388b097949&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426358463","title":"12周减重超13%！诺和诺德(NVO.US)新药amycretin片在中国申报临床获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2426358463","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2426358463?lang=zh_cn&edition=full","pubTime":"2024-04-10 18:04","pubTimestamp":1712743470,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，4月10日，中国国家药监局药品审评中心官网公示，诺和诺德1类新药amycretin片的临床试验申请获得受理。今年3月，诺和诺德公布了口服amycretin的最新临床试验结果。此外，amycretin展现良好的药代动力学特性，以及与其所开发的GLP-1类疗法类似的良好安全性、耐受性以及不良反应。此外，根据诺和诺德此前公开资料，该公司还预计在2024年下半年启动2期试验，在2型糖尿病患者中检视口服与皮下注射amycretin的疗效与安全性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1100661.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2426611077","title":"欧股“十一罗汉”｜阿斯麦与诺和诺德收跌约1.6%，SAP跌2.7%，欧莱雅则涨超1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2426611077","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2426611077?lang=zh_cn&edition=full","pubTime":"2024-04-10 00:31","pubTimestamp":1712680302,"startTime":"0","endTime":"0","summary":"阿斯麦控股荷兰阿姆斯特丹股价收跌1.58%，报899.30欧元，3月1日以来持续交投于900欧元附近，3月8日涨至958.40欧元创盘中历史新高。诺和诺德哥本哈根股价收跌1.59%，报857.70。思爱普收跌2.71%，报172.420欧元。欧莱雅收涨1.05%，阿斯利康收涨0.92%，罗氏控股收涨0.91%，雀巢收涨0.26%，赛诺菲收涨0.25%，诺华制药收涨0.02%，葛兰素史克伦敦股价收跌0.25%。LVMH集团收跌1.50%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404100031448b041c96&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404100031448b041c96&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426479946","title":"欧股“十一罗汉”｜，阿斯麦控股和LVMH涨约0.9%，诺和诺德涨约0.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2426479946","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2426479946?lang=zh_cn&edition=full","pubTime":"2024-04-09 01:31","pubTimestamp":1712597499,"startTime":"0","endTime":"0","summary":"阿斯麦控股荷兰阿姆斯特丹股价收涨0.88%，报913.70欧元，逼近3月7日所创收盘历史最高位949.20欧元和3月8日所创盘中历史最高位958.40欧元。诺和诺德哥本哈根股价收涨0.47%，报871.60。LVMH集团收涨0.94%，雀巢收涨0.37%，诺华制药收涨0.34%，罗氏控股收涨0.14%。阿斯利康收跌0.09%，思爱普收跌0.11%，欧莱雅收跌0.36%，赛诺菲收跌0.39%，葛兰素史克伦敦股价收跌0.58%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404090131428aff6f48&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404090131428aff6f48&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2425962846","title":"诺和诺德：“减肥神药 ”司美能缓解糖尿病人心衰症状","url":"https://stock-news.laohu8.com/highlight/detail?id=2425962846","media":"华尔街见闻","top":-1,"share":"https://www.laohu8.com/m/news/2425962846?lang=zh_cn&edition=full","pubTime":"2024-04-08 08:15","pubTimestamp":1712535310,"startTime":"0","endTime":"0","summary":"进一步支持了Wegovy用于治疗与肥胖相关疾病的潜力。","market":"hk","thumbnail":"https://static.tigerbbs.com/dcf8a1229dadd3b3d70f9b42478fc942","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/dcf8a1229dadd3b3d70f9b42478fc942"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3712122","is_publish_highlight":true,"gpt_icon":1},{"id":"2425454515","title":"隔夜美股全复盘(4.6)| 三大股指集体走高，贵金属板块领涨；特斯拉大跌4%，路透称其放弃推出低成本汽车计划，盘后大涨4%，马斯克称将发布无人驾驶出租车产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2425454515","media":"格隆汇","top":-1,"share":"https://www.laohu8.com/m/news/2425454515?lang=zh_cn&edition=full","pubTime":"2024-04-06 07:18","pubTimestamp":1712359090,"startTime":"0","endTime":"0","summary":"三大股指集体走高，贵金属板块领涨；特斯拉大跌4%，路透称其放弃推出低成本汽车计划，盘后大涨4%，马斯克称将发布无人驾驶出租车产品","market":"sg","thumbnail":"https://img7.gelonghui.com/column/2/140.png","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/140.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/716148","is_publish_highlight":false,"gpt_icon":0},{"id":"2425591465","title":"九源基因递交司美格鲁肽生物类似药上市申请，挑战减肥药巨头诺和诺德","url":"https://stock-news.laohu8.com/highlight/detail?id=2425591465","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2425591465?lang=zh_cn&edition=full","pubTime":"2024-04-06 01:36","pubTimestamp":1712338580,"startTime":"0","endTime":"0","summary":"随着全球减肥市场的持续火热，国内生物制药企业九源基因近日向国家药监局递交了司美格鲁肽注射液“吉优泰”的上市申请，标志着中国内地第一家申报上市的司美格鲁肽生物类似药正式进入审批阶段。据悉，九源基因的这款仿制药有望成为中国首款获批商业化的司美格鲁肽生物类似药，对全球减肥药巨头诺和诺德形成直接挑战。然而，九源基因的“吉优泰”若成功上市，将可能打破这一格局。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404060136548af4b41c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404060136548af4b41c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2424710224","title":"坎托菲茨杰拉德公司：重申Novo Nordisk(NVO.US)评级，由增持调整至增持评级,目标价1","url":"https://stock-news.laohu8.com/highlight/detail?id=2424710224","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2424710224?lang=zh_cn&edition=full","pubTime":"2024-04-01 21:14","pubTimestamp":1711977264,"startTime":"0","endTime":"0","summary":"坎托菲茨杰拉德公司：重申Novo Nordisk(NVO.US)评级，由增持调整至增持评级,目标价160.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024040121272987d0d353&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024040121272987d0d353&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.novonordisk.com","stockEarnings":[{"period":"1week","weight":-0.0145},{"period":"1month","weight":-0.0587},{"period":"3month","weight":0.1473},{"period":"6month","weight":0.2744},{"period":"1year","weight":0.4841},{"period":"ytd","weight":0.1862}],"compareEarnings":[{"period":"1week","weight":-0.0307},{"period":"1month","weight":-0.0486},{"period":"3month","weight":0.0264},{"period":"6month","weight":0.1756},{"period":"1year","weight":0.2022},{"period":"ytd","weight":0.0418}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Novo Nordisk A/S于1989年成立，由两家丹麦公司，诺德根措夫特A/S和Novo工业A/S的合并而成。诺和诺德是一家全球性医疗保健公司，糖尿病治疗的全球领先者。公司拥有业界最广泛的糖尿病产品组合，其中包括新一代胰岛素，现代的完整产品组合，以及作为一个人每日一次的GLP-1类似物之一。此外，诺和诺德在血友病关怀，生长激素疗法和激素替代疗法中也处于领先地位。","yearOnYearQuotes":[{"month":1,"riseRate":0.534884,"avgChangeRate":0.122207},{"month":2,"riseRate":0.604651,"avgChangeRate":0.027007},{"month":3,"riseRate":0.465116,"avgChangeRate":0.01259},{"month":4,"riseRate":0.627907,"avgChangeRate":0.015387},{"month":5,"riseRate":0.534884,"avgChangeRate":0.016207},{"month":6,"riseRate":0.697674,"avgChangeRate":0.026912},{"month":7,"riseRate":0.511628,"avgChangeRate":0.007273},{"month":8,"riseRate":0.511628,"avgChangeRate":0.000647},{"month":9,"riseRate":0.581395,"avgChangeRate":0.000639},{"month":10,"riseRate":0.511628,"avgChangeRate":-0.000902},{"month":11,"riseRate":0.627907,"avgChangeRate":0.028932},{"month":12,"riseRate":0.744186,"avgChangeRate":0.054828}],"exchange":"NYSE","name":"诺和诺德","nameEN":"Novo-Nordisk A/S"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺和诺德(NVO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺和诺德,NVO,诺和诺德股票,诺和诺德股票老虎,诺和诺德股票老虎国际,诺和诺德行情,诺和诺德股票行情,诺和诺德股价,诺和诺德股市,诺和诺德股票价格,诺和诺德股票交易,诺和诺德股票购买,诺和诺德股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺和诺德(NVO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}